A New Paradigm for Uterine Fibroid Treatment: Transcervical, Intrauterine Sonography-Guided Radiofrequency Ablation of Uterine Fibroids with the Sonata System.
A New Paradigm for Uterine Fibroid Treatment: Transcervical, Intrauterine Sonography-Guided Radiofrequency Ablation of Uterine Fibroids with the Sonata System.
复制标题
DOI：
10.1007/s13669-017-0194-2
复制
发表时间：
2017
影响因子：
0.5
通讯作者：
Toub DB
中科院分区：
文献类型：
--
作者：
Toub DB
这篇文章提供了在综合宫内超声引导下（Sonata系统）经子宫颈射频消融治疗子宫肌瘤的现有证据。已发表的使用Sonata系统治疗肌瘤的数据表明，消融后12个月，子宫肌瘤总体积（73.3%）和灌注体积（73.3%）、月经出血（72.3%）、症状严重程度（62.5%）的中位值显著降低，健康相关生活质量（127%）改善。FDA研究器械豁免下的临床试验正在进行中。Sonata系统是子宫肌瘤的一种很有前途的治疗方式。作为一种不需要全身麻醉或住院治疗的无切口微创治疗，它有可能重新定义目前症状性肌瘤的管理模式。
This article provides the current evidence related to transcervical radiofrequency ablation of uterine fibroids under integrated intrauterine sonography guidance (the Sonata System). Published data on the treatment of fibroids with the Sonata System has demonstrated significant median reductions in total (73.3%) and perfused (73.3%) uterine fibroid volume, menstrual bleeding (72.3%), symptom severity (62.5%), and improvements in health-related quality of life (127%) at 12 months post-ablation. A clinical trial under an FDA Investigational Device Exemption is in progress. The Sonata System is a promising treatment modality for uterine fibroids. As an incisionless, minimally invasive treatment that does not require general anesthesia or hospitalization, it has the potential for redefining the current paradigm for management of symptomatic fibroids.